Company attributes
Other attributes
Tubulis Therapeutics is a therapeutics company that is developing matched protein-drug conjugates. Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology.
Tubulis has the goal to broaden the therapeutic potential of antibody-drug conjugates by ushering in a new era and providing better patients' outcomes. The company designs, validates and develops transformative ADC assets with multi-specific modes of action that are integrated with disease biology and addresses significant technological and medical needs.
Tubulis’ proprietary dual ADC discovery and development approach is based on an initial screening platform with fast conjugation (P5) to rapidly identify novel protein-drug combinations for therapeutic application.
The company, through its team of experts, has built a collaborative network gathering expertise in chemistry, bioconjugation, antibody technologies, drug development, business, and clinical oncology.
